Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, Degarelix, leuprolide, LHRH | Leave a Comment »
In today’s news reports we comment on: The possible link between obesity and prostate cancer risk The economic impact of widespread prostate cancer screening in Europe The potential roles of tumor volume and PSMs in projecting need for adjuvant radiotherapy post-surgery Biochemical progression after treatment with degarelix (at up to 1 year)
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: adiponectin, adjuvant radiation, biochemical failure, cost, Degarelix, obesity, positive surgical margin, risk, tumor volume | Leave a Comment »
Before the coming of the PSA test, urologists used to use serum acid phosphatase levels (usually) and serum alkaline phosphatase (S-ALP) levels (less commonly) to assess the status of men at risk for or under treatment for metastatic prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: Degarelix, serum alkaline phosphatase | Leave a Comment »
Apparently Ferring Pharmaceuticals has finally been able to get Firmagon® approved as the new trade (brand) name for degarelix (their new LHRH antagonist) here in the USA. This is the same brand name as is used in Europe. Who knows why it took so long! The media release doesn’t say. In other news reports today [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: Degarelix, Height, quality of care, survival, tallness, vitamin B-6 | Leave a Comment »
A review article and three different sets of editorial comments have just been published in Oncology. They lay out the opinions of several specialists on the potential uses of degarelix — a recently approved, “second-generation” LHRH antagonist — in the management of prostate cancer. All the relevant articles are available in full on line.
Filed under: Management, Treatment | Tagged: Degarelix | Leave a Comment »
Ferring Pharmaceuticals has announced the company’s intent to initiate a randomized, controlled, multi-center trial of degarelix used as intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies.
Filed under: Drugs in development, Management, Treatment | Tagged: Degarelix, intermittent androgen deprivation therapy. IADT | Leave a Comment »
There are a significant number of relatively long-term news items in today’s report. Of most immediate interest to the majority of prostate cancer patients and educators we include reports on: The fact that over 70 percent of cancers thought to be unilateral at biopsy turn out to be bilateral post-surgery (which has implications for focal [...]
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biopsy, curcumin, Degarelix, focal therapy, nanoparticles, PROMIS, sexual function, TRAIL | 3 Comments »
We reported last December that the Committee for Medicinal Products for Human Use had adopted a positive opinion and had recommended marketing authorization for degarelix, a second-generation LHRH receptor antagonist, for the treatment of patients with advanced, hormone-dependent prostate cancer. According to a media release from Ferring Pharmaceuticals earlier today, the European Union has now [...]
Filed under: Drugs in development | Tagged: approval, Degarelix | Leave a Comment »
We had previously noted the approval of degarelix in Europe on December 23rd. It has been kindly pointed out to us that late on Christmas Eve the US Food and Drug Administration also approved the second generation LHRH antagonist degarelix for clinical use and marketing.
Filed under: Drugs in development | Tagged: Degarelix | Leave a Comment »
Several media reports from earlier in the day state that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending marketing authorization (in European Union nations) for degarelix, a second-generation LHRH receptor antagonist, for the treatment of patients with advanced, hormone-dependent [...]
Filed under: Uncategorized | Tagged: Degarelix | Leave a Comment »
Klotz et al. have now published the complete results of one of the Phase III clinical trials designed to evaluate the effectiveness and the safety of degarelix — a second-generation LHRH antagonist — in the management of hormone-sensitive prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: antagonist, Degarelix, LHRH | Leave a Comment »
There is a significant number of new reports today, addressing such issues as: data from a large series of robotic prostatectomy patients; the importance of positive surgical margins and their management; the significance of number of positive lymph nodes in N+M0 patients; evolving models of the role of testosterone in prostate cancer progression; and data [...]
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Degarelix, positive lymph nodes, robotic laparoscopic prostatectomy, surgical margins, testosterone | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site